Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye drug SCT520FF hopes to tackle wet AMD

NCT ID NCT06672536

Disease control Sponsor: Sinocelltech Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests an experimental drug called SCT520FF for wet age-related macular degeneration (AMD), a leading cause of vision loss. About 82 adults aged 45 to 80 will receive either SCT520FF or an existing treatment (EYLEA) via eye injections. Researchers will check safety, side effects, and whether the drug improves vision and reduces retinal swelling.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
SCT520FF (an experimental drug injected into the eye)
What this could lead to
If successful, this could offer a new treatment option for wet AMD, potentially improving vision and reducing the need for frequent eye injections.
What could go wrong
This is an early-phase trial with only 82 participants, so results may not apply to everyone. The drug may cause side effects or fail to improve vision better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 82 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2024

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Signed informed consent form. 2. Age≥45 years, ≤80 years，male or femal. 3. The study eye must meet the following criteria: Diagnosis of nAMD;Active MNV lesions secondary to nAMD; Total area of all types of lesions ≤12 optic disc areas; BCVA of the study eye 73\~19 letters. Exclusion Criteria: 1. Macular-related retinal pigment epithelial tears in the study eye; scar, fibrosis, atrophy or dense subfoveal exudation involving the fovea in the study eye. 2. Significant APD or opacity of the refractive medium and miosis in the study eye that affect visual acuity or fundus examination. 3. Aphakia (except intraocular lens) or posterior capsular rupture of the lens in the study eye. 4. The study eye has any eye diseases or medical history other than nAMD that may affect central vision and/or macular examine. 5. MNV caused by non-nAMD exists in the study eye . 6. Active inflammation or infection in either eye before randomization. 7. Known allergy to any component of the study intervention or history of allergy to fluorescein or indocyanine green, any anesthetics or antimicrobial agents used during the course of the study. 8. Abnormal liver and kidney function. 9. Poorly-controlled blood pressure before randomization. 10. History of a cardiovascular and cerebrovascular events, including myocardial infarction, unstable angina pectoris, cerebrovascular accidents (including TIA), other thromboembolic diseases (such as thromboembolic angiitis, etc) within 6 months before randomization. 11. Evidence of significant uncontrolled concomitant diseases. 12. Participated in any drug (other than vitamins and minerals) or device clinical trials within 3 months or the duration of 5 half-lives of the study drug (which is longer) before randomization and have used the test drug or received device treatment. 13. Pregnant, lactating women who can not take contraceptive measures during the trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NAMD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

nemaline myopathy wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NAMD

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Tianjin Medical University Eye Hospital

    RECRUITING

    Tianjing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.